机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[2]Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China[3]School of Food Science and Engineering, Guiyang University, Guizhou, China[4]Rehabilitation Department, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China[5]Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[6]Department of Interventional Radiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[7]Rehabilitation Department, Shanghai Huayang Community Health Center, Shanghai, China[8]Department of Otorhinolaryngology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
the National Natural Science Foundation of China (82002495), Research Fund of Shanghai Tongren Hospital (TRKYRC-xx202205, TRKYRC-xx202212, TRKYRC-xx202213), Fundamental Research Funds for the Central Universities (YG2025QNB53,
YG2022QN117), and Research Fund of Key Laboratory for Translational
Research and Innovative Therapeutics of Gastrointestinal Oncology
(ZDSYS-2021-04).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|4 区医学
小类|4 区医学:内科
最新[2025]版:
大类|4 区医学
小类|4 区医学:内科
第一作者:
第一作者机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[2]Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[5]Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
推荐引用方式(GB/T 7714):
Liu Ying,Chen Taoying,Tang Li,et al.SESTD1 as a potential prognostic biomarker associated with tumor aggressiveness and immune infiltration in hepatocellular carcinoma[J].Clinics (Sao Paulo, Brazil).2025,80:100796.doi:10.1016/j.clinsp.2025.100796.
APA:
Liu Ying,Chen Taoying,Tang Li,Cheng Daqing,Xu Ming...&Cheng Sheng.(2025).SESTD1 as a potential prognostic biomarker associated with tumor aggressiveness and immune infiltration in hepatocellular carcinoma.Clinics (Sao Paulo, Brazil),80,
MLA:
Liu Ying,et al."SESTD1 as a potential prognostic biomarker associated with tumor aggressiveness and immune infiltration in hepatocellular carcinoma".Clinics (Sao Paulo, Brazil) 80.(2025):100796